Morgan Stanley analyst Michael Ulz reiterates Viking Therapeutics (NASDAQ:VKTX) with a Overweight and maintains $105 price target.
Morgan Stanley Reiterates Overweight on Viking Therapeutics, Maintains $105 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.